nimustine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boon, U; Cuppen, E; de Maaker, M; de Ruiter, J; Duran, K; Esteller, M; Gevensleben, H; Hogervorst, F; Jonkers, J; Józwiak, K; Kloosterman, W; Kristel, P; Lips, E; Majewski, I; Marangoni, E; Moutinho, C; Mulder, L; Ter Brugge, P; Turner, N; van der Burg, E; van Roosmalen, M; Wesseling, J | 1 |
1 other study(ies) available for nimustine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Cisplatin; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Fusion; Genes, BRCA1; Humans; Melphalan; Mice; Mutation; Neoplasm Transplantation; Nimustine; Phthalazines; Piperazines; Promoter Regions, Genetic; Triple Negative Breast Neoplasms | 2016 |